Moderna Inc (MRNA)
166.61
+2.60
(+1.59%)
USD |
NASDAQ |
May 24, 16:00
166.31
-0.30
(-0.18%)
After-Hours: 20:00
Moderna SG&A Expense (Annual): 1.549B for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.549B |
| December 31, 2022 | 1.132B |
| December 31, 2021 | 567.00M |
| December 31, 2020 | 188.00M |
| Date | Value |
|---|---|
| December 31, 2019 | 110.00M |
| December 31, 2018 | 94.25M |
| December 31, 2017 | 64.72M |
| December 31, 2016 | 57.45M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
110.00M
Minimum
2019
1.549B
Maximum
2023
709.20M
Average
567.00M
Median
2021
SG&A Expense (Annual) Benchmarks
| Eli Lilly and Co | 6.941B |
| Merck & Co Inc | 10.50B |
| Pfizer Inc | 14.77B |
| Bristol-Myers Squibb Co | 7.772B |
| Novavax Inc | 468.95M |